At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 105 enrolled
Drug / intervention
eltrombopagdrug
Likely dose
eltrombopag 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids
In Brief
A Phase 2 clinical trial evaluating eltrombopag for Immune Thrombocytopenic Purpura (ITP). Completed, enrolled 105 participants across 32 sites in 15 countries.
Detailed Summary
The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with steroids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenic Purpura (ITP)
CountriesAustria, Brazil, Chile, France, Greece, Italy, Japan, Mexico, Oman, Russia, Spain, Switzerland, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartNov 2018
Primary CompletionOct 2021
Study CompletionOct 2022
TodayJul 2026
First PostedMay 15, 2018
Enrollment StartNov 2, 2018
Primary CompletionOct 22, 2021
Study CompletionOct 3, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.1 years ago
Interventions
eltrombopagdrug
12.5, 25, 50 and 75 mg tablets for oral use once daily